Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-23T11:35:55.626Z Has data issue: false hasContentIssue false
  • English
  • Français

Repositioning anticancer drugs as novel COVID-19 antivirals: targeting structural and functional similarities between viral proteins and cancer

Part of: Molecular understanding of Covid pathogenesis, immunity and therapeutics

Published online by Cambridge University Press:  22 April 2022

Zheng Yao Low Open the ORCID record for Zheng Yao Low [Opens in a new window] ,
Ashley Jia Wen Yip Open the ORCID record for Ashley Jia Wen Yip [Opens in a new window]  and
Sunil Kumar Lal Open the ORCID record for Sunil Kumar Lal [Opens in a new window]
Zheng Yao Low
Affiliation:
School of Science, Monash University Malaysia, 47500 Bandar Sunway, Selangor DE, Malaysia
Ashley Jia Wen Yip
Affiliation:
School of Science, Monash University Malaysia, 47500 Bandar Sunway, Selangor DE, Malaysia
Sunil Kumar Lal*
Affiliation:
School of Science, Monash University Malaysia, 47500 Bandar Sunway, Selangor DE, Malaysia Tropical Medicine and Biology Platform, Monash University Malaysia, 47500 Bandar Sunway, Selangor DE, Malaysia
*
Author for correspondence: Sunil Kumar Lal, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The current COVID-19 pandemic contributed by the SARS-CoV-2 has put in place an urgent need for new and promising antiviral therapeutics. The viral RNA-dependent RNA polymerase (RdRp) enzyme plays a vital role in viral replication for all RNA viruses, including SARS-CoV-2, thereby making it a prime and promising candidate for novel antiviral targeting. Interestingly, the human telomerase reverse transcriptase (hTERT), a common catalytic subunit of the telomerase enzyme in many cancers, has also been identified with structural and functional similarities to the viral RdRp. Therefore, it becomes essential to evaluate and consider anticancer drugs that target hTERT towards antiviral RdRp activity, and vice versa. For instance, Floxuridine, an hTERT inhibitor, and VX-222, a hepatitis C virus RdRp inhibitor, are now gaining recognition as a potential antiviral against SARS-CoV-2 and anti-hTERT for cancer, simultaneously. While limited studies on hTERT inhibitors for use as viral RdRp, and anti-RdRp inhibitors as hTERT inhibitors are available, in this review, we aim at bringing to light this close structural and functional relationship between both these enzymes. We punctuate this idea with specific examples on how potential anticancer inhibitors can effectively be brought to use as inhibitors against the SARS-CoV-2 virus, a relatively new pathogen, compared to the very well-studied field of cancer research.

Keywords

AnticancerantiviralcancerCOVID-19drug repositioningdrug repurposinghTERTinhibitionRdRpSARS-CoV-2virus
Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 24 , 2022 , e20
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Worldometers Coronavirus Update, COVID-19 Virus Pandemic. Available at https://www.worldometers.info/coronavirus/ (Accessed January 2022).Google Scholar
Ye, Z et al. (2020) Zoonotic origins of human coronaviruses. International Journal of Biological Sciences 16, 1686–1697.CrossRefGoogle ScholarPubMed
Zumla, A, Hui, D and Perlman, S (2015) Middle East respiratory syndrome. The Lancet 386, 995–1007.CrossRefGoogle ScholarPubMed
Peiris, J et al. (2003) The severe acute respiratory syndrome. New England Journal of Medicine 349, 2431–2441.CrossRefGoogle ScholarPubMed
WHO Director-General's opening remarks at the media briefing on COVID-19. Available at https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020 (Accessed December 2021).Google Scholar
Shereen, M et al. (2020) COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses. Journal of Advanced Research 24, 91–98.CrossRefGoogle ScholarPubMed
Wu, D et al. (2020) The SARS-CoV-2 outbreak: what we know. International Journal of Infectious Diseases 94, 44–48.CrossRefGoogle ScholarPubMed
Low, Z et al. (2021) SARS coronavirus outbreaks past and present – a comparative analysis of SARS-CoV-2 and its predecessors. Virus Genes 57, 307–317.CrossRefGoogle ScholarPubMed
Fehr, AR and Perlman, S (2015) Coronaviruses: An Overview of Their Replication and Pathogenesis, Coronaviruses, Methods in Molecular Biology. New York: Humana Press, pp. 1–23.Google Scholar
Chen, Y, Liu, Q and Guo, D (2020) Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of Medical Virology 92, 2249–2249.CrossRefGoogle ScholarPubMed
Naqvi, A et al. (2020) Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 1866, 165878.CrossRefGoogle ScholarPubMed
Astuti, I and Ysrafil, (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14, 407–412.CrossRefGoogle ScholarPubMed
Kumar, S et al. (2020) Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In Saxena, SK (ed.), Medical Virology: From Pathogenesis to Disease Control. Springer Nature Singapore Pte Ltd: Springer, pp. 23–31.Google Scholar
Afdhal, N et al. (2014) Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 370, 1889–1898.CrossRefGoogle ScholarPubMed
Min, J et al. (2020) A cell-based reporter assay for screening inhibitors of MERS coronavirus RNA-dependent RNA polymerase activity. Journal of Clinical Medicine 9, 2399.CrossRefGoogle ScholarPubMed
Amin, S and Jha, T (2020) Fight against novel coronavirus: a perspective of medicinal chemists. European Journal of Medicinal Chemistry 201, 112559.CrossRefGoogle ScholarPubMed
Wang, Q et al. (2020) Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell 182, 417–428.CrossRefGoogle ScholarPubMed
Low, Z, Farouk, I and Lal, S (2020) Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses 12, 1058.CrossRefGoogle ScholarPubMed
WHO Solidarity Trial Consortium (2021) Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. New England Journal of Medicine 384, 497–511.CrossRefGoogle Scholar
Dyer, O (2020) Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. BMJ, 371. https://doi.org/10.1136/bmj.m4057.Google ScholarPubMed
Merck (2021) Merck and Ridgeback's investigational oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study – Merck.com. Available at https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ (Accessed December 2021).Google Scholar
Maida, Y, Yasukawa, M and Masutomi, K (2016) De novo RNA synthesis by RNA-dependent RNA polymerase activity of telomerase reverse transcriptase. Molecular and Cellular Biology 36, 1248–1259.CrossRefGoogle ScholarPubMed
Machitani, M et al. (2020) RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19. Cancer Science 111, 3976–3984.CrossRefGoogle ScholarPubMed
Hillen, H et al. (2020) Structure of replicating SARS-CoV-2 polymerase. Nature 584, 154–156.CrossRefGoogle ScholarPubMed
Gao, Y et al. (2020) Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779–782.CrossRefGoogle ScholarPubMed
Wu, J and Gong, P (2018) Visualizing the nucleotide addition cycle of viral RNA-dependent RNA polymerase. Viruses 10, 24.CrossRefGoogle ScholarPubMed
Maida, Y and Masutomi, K (2015) Telomerase reverse transcriptase moonlights: therapeutic targets beyond telomerase. Cancer Science 106, 1486–1492.CrossRefGoogle ScholarPubMed
Gilson, E and Ségal-Bendirdjian, E (2010) The telomere story or the triumph of an open-minded research. Biochimie 92, 321–326.CrossRefGoogle ScholarPubMed
Wyatt, H, West, S and Beattie, T (2010) InTERTpreting telomerase structure and function. Nucleic Acids Research 38, 5609–5622.CrossRefGoogle ScholarPubMed
Maida, Y et al. (2009) An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461, 230–235.CrossRefGoogle ScholarPubMed
Roake, C and Artandi, S (2020) Regulation of human telomerase in homeostasis and disease. Nature Reviews Molecular Cell Biology 21, 384–397.CrossRefGoogle ScholarPubMed
Jafri, M et al. (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Medicine 8, 1–18.CrossRefGoogle ScholarPubMed
Somanathan, I and Baysdorfer, C (2018) A bioinformatics approach to identify telomere sequences. BioTechniques 65, 20–25.CrossRefGoogle ScholarPubMed
Lai, C, Miller, M and Collins, K (2003) Roles for RNA in telomerase nucleotide and repeat addition processivity. Molecular Cell 11, 1673–1683.CrossRefGoogle ScholarPubMed
Takahashi, K and Yamanaka, S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676.CrossRefGoogle ScholarPubMed
Kyo, S et al. (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Science 99, 1528–1538.CrossRefGoogle ScholarPubMed
Rafnar, T et al. (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nature Genetics 41, 221–227.CrossRefGoogle ScholarPubMed
Yasukawa, M et al. (2020) CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nature Communications 11, 1–18.CrossRefGoogle ScholarPubMed
Cano-Soldado, P and Pastor-Anglada, M (2011) Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Medicinal Research Reviews 32, 428–457.CrossRefGoogle ScholarPubMed
Jordheim, L et al. (2013) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Reviews Drug Discovery 12, 447–464.CrossRefGoogle ScholarPubMed
Ahmad, M and Dealwis, C (2013) The structural basis for the allosteric regulation of ribonucleotide reductase. Progress in Molecular Biology and Translational Science 117, 389–410.CrossRefGoogle ScholarPubMed
Tárkányi, I and Aradi, J (2008) Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Biochimie 90, 156–172.CrossRefGoogle ScholarPubMed
Richman, D (2001) HIV chemotherapy. Nature 410, 995–1001.CrossRefGoogle ScholarPubMed
Zeng, X et al. (2018) Administration of a nucleoside analog promotes cancer cell death in a telomerase-dependent manner. Cell Reports 23, 3031–3041.CrossRefGoogle Scholar
Wu, C et al. (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 10, 766–788.CrossRefGoogle ScholarPubMed
Tomar, P, Krugliak, M and Arkin, I (2021) Blockers of the SARS-CoV-2 3a channel identified by targeted drug repurposing. Viruses 13, 532.CrossRefGoogle ScholarPubMed
Yi, G et al. (2011) Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and Filibuvir. Antimicrobial Agents and Chemotherapy 56, 830–837.CrossRefGoogle ScholarPubMed
Di Bisceglie, A et al. (2014) VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 26, 761–773.CrossRefGoogle ScholarPubMed
Hong, J et al. (2019) Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Scientific Reports 9, 1–7.CrossRefGoogle ScholarPubMed
PubChem Compound Summary for CID 148121, Pralatrexate. Available at https://pubchem.ncbi.nlm.nih.gov/compound/Pralatrexate (Accessed December 2021).Google Scholar
Serova, M et al. (2010) Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. British Journal of Cancer 104, 272–280.CrossRefGoogle ScholarPubMed
Zhang, H et al. (2020) A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLoS Computational Biology 16, e1008489.CrossRefGoogle ScholarPubMed
Bae, J et al. (2021) Antiviral efficacy of Pralatrexate against SARS-CoV-2. Biomolecules & Therapeutics 29, 268–272.CrossRefGoogle ScholarPubMed
Li, X et al. (2018) Corilagin, a promising medicinal herbal agent. Biomedicine & Pharmacotherapy 99, 43–50.CrossRefGoogle ScholarPubMed
Kakiuchi, N et al. (1985) Inhibitory effect of tannins on reverse transcriptase from RNA tumor virus. Journal of Natural Products 48, 614–621.CrossRefGoogle ScholarPubMed
Jia, L et al. (2017) Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting snail-glycolysis pathways. Oncology Reports 38, 2464–2470.CrossRefGoogle ScholarPubMed
Zheng, Z et al. (2016) Bioguided fraction and isolation of the antitumor components from Phyllanthus niruri L. BioMed Research International 2016, 1–7.Google ScholarPubMed
Tong, Y et al. (2018) Corilagin inhibits breast cancer growth via reactive oxygen species-dependent apoptosis and autophagy. Journal of Cellular and Molecular Medicine 22, 3795–3807.CrossRefGoogle ScholarPubMed
Reddy, B et al. (2018) A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Research 150, 47–59.CrossRefGoogle ScholarPubMed
Hiremath, S et al. (2021) In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2. 3 Biotech 11, 1–18.CrossRefGoogle ScholarPubMed
Li, Q et al. (2021) Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta Pharmaceutica Sinica B 11, 1555–1567.CrossRefGoogle ScholarPubMed
Minskaia, E et al. (2006) Discovery of an RNA virus 3’->5’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proceedings of the National Academy of Sciences 103, 5108–5113.CrossRefGoogle ScholarPubMed
Ogando, N et al. (2019) The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity. Frontiers in Microbiology 10, 1813.CrossRefGoogle ScholarPubMed
Yan, L et al. (2021) Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell 184, 3474–3485.CrossRefGoogle ScholarPubMed
Viswanathan, T et al. (2021) A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2′-O methylation of its first nucleotide. Nature Communications 12, 3287.CrossRefGoogle ScholarPubMed
Roy, M et al. (2018) Lycorine: a prospective natural lead for anticancer drug discovery. Biomedicine & Pharmacotherapy 107, 615–624.CrossRefGoogle ScholarPubMed
Chen, H et al. (2020) Antiviral activity of lycorine against Zika virus in vivo and in vitro. Virology 546, 88–97.CrossRefGoogle ScholarPubMed
Li, S et al. (2005) Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Research 67, 18–23.CrossRefGoogle ScholarPubMed
Shen, L et al. (2019) High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. Journal of Virology 93, e00023–19.CrossRefGoogle ScholarPubMed
Ren, P et al. (2021) A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta Pharmacologica Sinica 43, 483–493. https://doi.org/10.1038/s41401-021-00668-7CrossRefGoogle ScholarPubMed
Zhang, Y et al. (2020) Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerging Microbes & Infections 9, 1170–1173.CrossRefGoogle ScholarPubMed
Jin, Y et al. (2021) Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. Phytomedicine 86, 153440.CrossRefGoogle ScholarPubMed
Li, C et al. (2020) Lycorine hydrochloride inhibits cell proliferation and induces apoptosis through promoting FBXW7-MCL1 axis in gastric cancer. Journal of Experimental & Clinical Cancer Research 39, 1–16.CrossRefGoogle ScholarPubMed
Ying, X et al. (2017) Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway. Science China Life Sciences 60, 417–428.CrossRefGoogle ScholarPubMed